Morgan Stanley Magenta Therapeutics, Inc. Transaction History

Morgan Stanley

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.62 - $0.79 $310,107 - $395,136	-500,173 Reduced 96.74%	16,866 $12,000
Q1 2023 May 15, 2023	BUY	$0.41 - $0.86 $179,307 - $376,108	437,336 Added 548.71%	517,039 $408,000
Q4 2022 Feb 14, 2023	BUY	$0.36 - $1.59 $23,143 - $102,217	64,288 Added 417.05%	79,703 $31,000
Q3 2022 Nov 14, 2022	SELL	$1.26 - $2.09 $18,133 - $30,079	-14,392 Reduced 48.28%	15,415 $22,000
Q2 2022 Oct 27, 2022	BUY	$0.97 - $3.08 $12,878 - $40,893	13,277 Added 80.32%	29,807 $35,000
Q2 2022 Aug 15, 2022	BUY	$0.97 - $3.08 $12,878 - $40,893	13,277 Added 80.32%	29,807 $35,000
Q1 2022 Oct 27, 2022	SELL	$2.55 - $5.23 $33,856 - $69,438	-13,277 Reduced 44.54%	16,530 $49,000
Q1 2022 May 13, 2022	SELL	$2.55 - $5.23 $28,483 - $58,419	-11,170 Reduced 40.32%	16,530 $49,000
Q4 2021 Feb 14, 2022	BUY	$4.43 - $8.33 $38,789 - $72,937	8,756 Added 46.22%	27,700 $123,000
Q3 2021 Nov 15, 2021	BUY	$6.07 - $9.89 $114,990 - $187,356	18,944 New	18,944 $138,000

442K

Ticker MGTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,890,500
Description
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that ca...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.